{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:27:16Z","timestamp":1790803636567,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmorw.2026.100682","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:01:05Z","timestamp":1769788865000},"page":"100682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Artificial intelligence for clinical trial design, conduct, and analysis: a narrative review"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2523-137X","authenticated-orcid":false,"given":"D.G.","family":"Knapen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0897-2747","authenticated-orcid":false,"given":"M.","family":"van Kruchten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-6835","authenticated-orcid":false,"given":"D.J.A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8714","authenticated-orcid":false,"given":"K.E.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-315X","authenticated-orcid":false,"given":"R.S.N.","family":"Fehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2026.100682_bib1","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41598-024-53211-z","article-title":"Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials","volume":"14","author":"Markey","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmorw.2026.100682_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmorw.2026.100682_bib3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/d41573-024-00068-6","article-title":"Efficiency, effectiveness and productivity in pharmaceutical R&D","volume":"23","author":"Roland","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmorw.2026.100682_bib4","first-page":"447","article-title":"Parsing clinical success rates","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.esmorw.2026.100682_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2024.101589","article-title":"SEETrials: leveraging large language models for safety and efficacy extraction in oncology clinical trials","volume":"50","author":"Lee","year":"2024","journal-title":"Inform Med Unlocked"},{"key":"10.1016\/j.esmorw.2026.100682_bib7","series-title":"Proceedings of the 2023 ACM Conference on Information Technology for Social Good (GoodIT \u201923)","first-page":"396","article-title":"CliniDigest: a case study in large language model based large-scale summarization of clinical trial descriptions","author":"White","year":"2023"},{"key":"10.1016\/j.esmorw.2026.100682_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jamia\/ocad218","article-title":"AutoCriteria: a generalizable clinical trial eligibility criteria extraction system powered by large language models","volume":"31","author":"Datta","year":"2024","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.esmorw.2026.100682_bib9","first-page":"365","article-title":"Automated mass extraction of over 680,000 PICOs from clinical study abstracts using generative AI: a proof-of-concept study","volume":"38","author":"Reason","year":"2024","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13326-024-00305-2","article-title":"Comparing generative and extractive approaches to information extraction from abstracts describing randomized clinical trials","volume":"15","author":"Witte","year":"2024","journal-title":"J Biomed Semantics"},{"key":"10.1016\/j.esmorw.2026.100682_bib11","doi-asserted-by":"crossref","DOI":"10.2196\/48996","article-title":"Automated paper screening for clinical reviews using large language models: data analysis study","volume":"26","author":"Guo","year":"2024","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jrsm.1715","article-title":"Can large language models replace humans in systematic reviews? Evaluating GPT-4\u2019s efficacy in screening and extracting data from peer-reviewed and grey literature in multiple languages","volume":"15","author":"Khraisha","year":"2024","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.esmorw.2026.100682_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jamia\/ocaf030","article-title":"Enhancing systematic literature reviews with generative artificial intelligence: development, applications, and performance evaluation","volume":"32","author":"Li","year":"2025","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.esmorw.2026.100682_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111746","article-title":"Large language models for conducting systematic reviews: on the rise, but not yet ready for use\u2014a scoping review","volume":"181","author":"Lieberum","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmorw.2026.100682_bib15","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research performance status work group","volume":"27","author":"Magnuson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib16","series-title":"Proceedings of the 2023 Conference on Empirical Methods in Natural Language Processing (EMNLP 2023)","first-page":"12461","article-title":"AutoTrial: prompting language models for clinical trial design","author":"Wang","year":"2023"},{"key":"10.1016\/j.esmorw.2026.100682_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jamia\/ocae311","article-title":"Analysis of eligibility criteria clusters based on large language models for clinical trial design","volume":"32","author":"Bornet","year":"2025","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.esmorw.2026.100682_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.esmorw.2026.100682_bib19","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0164","article-title":"Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials","volume":"13","author":"Jreich","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41746-025-01886-7","article-title":"A scoping review of artificial intelligence applications in clinical trial risk assessment","volume":"8","author":"Teodoro","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chembiol.2016.07.023","article-title":"A data-driven approach to predicting successes and failures of clinical trials","volume":"23","author":"Gayvert","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.esmorw.2026.100682_bib22","article-title":"Machine learning with statistical imputation for predicting drug approval","volume":"1","author":"Lo","year":"2019","journal-title":"Harvard Data Science Review"},{"key":"10.1016\/j.esmorw.2026.100682_bib23","article-title":"HINT: Hierarchical Interaction Network for clinical-trial-outcome predictions","volume":"3","author":"Fu","year":"2022","journal-title":"Patterns (NY)"},{"key":"10.1016\/j.esmorw.2026.100682_bib24","series-title":"Proceedings of the 14th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB 2023)","first-page":"1","article-title":"SPOT: Sequential Predictive mOdeling of clinical Trial outcome with meta-learning","author":"Wang","year":"2023"},{"key":"10.1016\/j.esmorw.2026.100682_bib25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/cpt.3008","article-title":"Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence","volume":"114","author":"Aliper","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmorw.2026.100682_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.drudis.2019.12.014","article-title":"Key indicators of phase transition for clinical trials through machine learning","volume":"25","author":"Feijoo","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.esmorw.2026.100682_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju229","article-title":"Adult cancer clinical trials that fail to complete: an epidemic?","volume":"106","author":"Stensland","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmorw.2026.100682_bib28","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-10-0133","article-title":"A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies","volume":"16","author":"Cheng","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1158\/1078-0432.CCR-10-1730","article-title":"Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP\u2013sponsored clinical trials","volume":"17","author":"Cheng","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib30","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1158\/1078-0432.CCR-16-0338","article-title":"Challenges facing early phase trials sponsored by the national cancer institute: an analysis of corrective action plans to improve accrual","volume":"22","author":"Massett","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djad013","article-title":"Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis","volume":"115","author":"Chow","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmorw.2026.100682_bib32","series-title":"Proceedings of The Web Conference 2020 (WWW \u201920)","first-page":"1029","article-title":"DeepEnroll: patient-trial matching with deep embedding and entailment prediction","author":"Zhang","year":"2020"},{"key":"10.1016\/j.esmorw.2026.100682_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jamiaopen\/ooaa002","article-title":"Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients","volume":"3","author":"Alexander","year":"2020","journal-title":"JAMIA Open"},{"key":"10.1016\/j.esmorw.2026.100682_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1200\/CCI.19.00079","article-title":"Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center","volume":"4","author":"Beck","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.esmorw.2026.100682_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2024.104649","article-title":"Criteria2Query 3.0: leveraging generative large language models for clinical trial eligibility query generation","volume":"154","author":"Park","year":"2024","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.esmorw.2026.100682_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jamia\/ocab228","article-title":"A systematic review on natural language processing systems for eligibility prescreening in clinical research","volume":"29","author":"Idnay","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.esmorw.2026.100682_bib37","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100682_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e8668","article-title":"Differential dropout and bias in randomised controlled trials: when it matters and when it may not","volume":"346","author":"Bell","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.esmorw.2026.100682_bib39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1191\/1740774504cn032oa","article-title":"Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals","volume":"1","author":"Wood","year":"2004","journal-title":"Clin Trials"},{"key":"10.1016\/j.esmorw.2026.100682_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1109\/TLT.2019.2911608","article-title":"From lab to production: lessons learnt and real-life challenges of an early student-dropout prevention system","volume":"12","author":"Ortigosa","year":"2019","journal-title":"IEEE Trans Learn Technol"},{"key":"10.1016\/j.esmorw.2026.100682_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jclinepi.2006.11.023","article-title":"Systematic review identifies number of strategies important for retaining study participants","volume":"60","author":"Robinson","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.esmorw.2026.100682_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12874-017-0310-z","article-title":"Participant retention practices in longitudinal clinical research studies with high retention rates","volume":"17","author":"Abshire","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmorw.2026.100682_bib43","doi-asserted-by":"crossref","DOI":"10.2196\/47217","article-title":"Evaluation of the current state of chatbots for digital health: scoping review","volume":"25","author":"Xue","year":"2023","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12916-020-01773-w","article-title":"Use of wearable biometric monitoring devices to measure outcomes in randomized clinical trials: a methodological systematic review","volume":"18","author":"Possamai","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41746-023-00767-1","article-title":"Evidence from ClinicalTrials.gov on the growth of digital health technologies in neurology trials","volume":"6","author":"Masanneck","year":"2023","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41531-024-00721-2","article-title":"Using a smartwatch and smartphone to assess early Parkinson\u2019s disease in the WATCH-PD study over 12 months","volume":"10","author":"Adams","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.esmorw.2026.100682_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41746-024-01322-2","article-title":"V3+ extends the V3 framework to ensure user-centricity and scalability of sensor-based digital health technologies","volume":"8","author":"Bakker","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jamia\/ocy052","article-title":"Good intentions are not enough: how informatics interventions can worsen inequality","volume":"25","author":"Veinot","year":"2018","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.esmorw.2026.100682_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.artmed.2023.102701","article-title":"Natural language processing with machine learning methods to analyze unstructured patient-reported outcomes derived from electronic health records: a systematic review","volume":"146","author":"Sim","year":"2023","journal-title":"Artif Intell Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40264-024-01505-6","article-title":"Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health\/medical records: a scoping review","volume":"48","author":"Golder","year":"2025","journal-title":"Drug Saf"},{"key":"10.1016\/j.esmorw.2026.100682_bib52","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.jpainsymman.2025.01.019","article-title":"NLP for analyzing electronic health records and clinical notes in cancer research: a review","volume":"69","author":"Bilal","year":"2025","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.esmorw.2026.100682_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf021","article-title":"The use of large language models to enhance cancer clinical trial educational materials","volume":"9","author":"Gao","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.esmorw.2026.100682_bib54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41746-024-01106-8","article-title":"Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy","volume":"7","author":"McGenity","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41571-025-00991-6","article-title":"Artificial intelligence in digital pathology \u2014 time for a reality check","volume":"22","author":"Aggarwal","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100682_bib56","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232471","article-title":"Generating synthetic data for medical imaging","volume":"312","author":"Koetzier","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.esmorw.2026.100682_bib57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13244-022-01287-4","article-title":"Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC","volume":"13","author":"deSouza","year":"2022","journal-title":"Insights Imaging"},{"key":"10.1016\/j.esmorw.2026.100682_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13244-019-0764-0","article-title":"Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL subcommittee of the European Society of Radiology (ESR)","volume":"10","author":"deSouza","year":"2019","journal-title":"Insights Imaging"},{"key":"10.1016\/j.esmorw.2026.100682_bib60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/antibiotics13121203","article-title":"Artificial intelligence and machine learning applications to pharmacokinetic modeling and dose prediction of antibiotics: a scoping review","volume":"13","author":"Varela-Rey","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.esmorw.2026.100682_bib61","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/psp4.12831","article-title":"Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under roblitinib (FGF401) drug treatment","volume":"11","author":"Wilbaux","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.esmorw.2026.100682_bib62","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cpt.3176","article-title":"Reinforcement learning and PK-PD models integration to personalize the adaptive dosing protocol of erdafitinib in patients with metastatic urothelial carcinoma","volume":"115","author":"De Carlo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmorw.2026.100682_bib63","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40262-024-01409-9","article-title":"Machine learning methods for precision dosing in anticancer drug therapy: a scoping review","volume":"63","author":"Teplytska","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmorw.2026.100682_bib64","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmorw.2026.100682_bib65","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41568-021-00408-3","article-title":"Harnessing multimodal data integration to advance precision oncology","volume":"22","author":"Boehm","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmorw.2026.100682_bib66","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/s41591-024-02993-w","article-title":"Prediction of recurrence risk in endometrial cancer with multimodal deep learning","volume":"30","author":"Volinsky-Fremond","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr1576","article-title":"A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer","volume":"11","author":"Mao","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.esmorw.2026.100682_bib68","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1038\/s41467-023-41820-7","article-title":"Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer","volume":"14","author":"Crispin-Ortuzar","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmorw.2026.100682_bib69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41698-025-00900-1","article-title":"Foundation model-driven multimodal prognostic prediction in patients undergoing primary surgery for high-grade serous ovarian cancer","volume":"9","author":"Bi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmorw.2026.100682_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s43018-024-00891-1","article-title":"Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence","volume":"6","author":"Keyl","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmorw.2026.100682_bib71","article-title":"Medical digital twins: enabling precision medicine and medical artificial intelligence","volume":"7","author":"Sad\u00e9e","year":"2025","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.esmorw.2026.100682_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: a scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib73","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.3390\/jcm14103574","article-title":"Exploring the potential of digital twins in cancer treatment: a narrative review of reviews","volume":"14","author":"Giansanti","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.esmorw.2026.100682_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188572","article-title":"The case for AI-driven cancer clinical trials \u2013 the efficacy arm in silico","volume":"1876","author":"Kolla","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.esmorw.2026.100682_bib75","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/psp4.12669","article-title":"Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility","volume":"10","author":"Musuamba","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100682_bib76","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/bib\/bby043","article-title":"In silico clinical trials: concepts and early adoptions","volume":"20","author":"Pappalardo","year":"2019","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.esmorw.2026.100682_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104324","article-title":"The feasibility of using real world data as external control arms in oncology trials","volume":"30","author":"Lin","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.esmorw.2026.100682_bib85","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials \u2013 a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.esmorw.2026.100682_bib87","doi-asserted-by":"crossref","DOI":"10.2196\/66821","article-title":"Augmenting insufficiently accruing oncology clinical trials using generative models: validation study","volume":"27","author":"Kababji","year":"2025","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib88","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2217\/cer-2018-0032","article-title":"Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib","volume":"7","author":"Davies","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.esmorw.2026.100682_bib90","article-title":"How to critically appraise and direct the trajectory of AI development and application in oncology","volume":"5","author":"Fehrmann","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.esmorw.2026.100682_bib92","article-title":"ESMO Basic Requirements for AI-Based Biomarkers in Oncology (EBAI)","author":"Aldea","year":"2025","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:24:34Z","timestamp":1774488274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":80,"alternative-id":["S2949820126000019"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100682","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial intelligence for clinical trial design, conduct, and analysis: a narrative review","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100682"}}